| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10944 | CBB3001 | CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM. |
|
| DC12623 | CBK289001 | CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM.. |
|
| DC10617 | CBL0137 Featured | CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. |
|
| DC8377 | CC-115 Featured | CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. |
|
| DC10146 | CC-122（Avadomide） Featured | CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
|
| DC8497 | CC-223 Featured | CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). |
|
| DC7096 | CC-401 Featured | CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
|
| DC20866 | CC-671 Featured | CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively. |
|
| DC11588 | CC-885 Featured | CC-885 (CC 885, CC885) is a novel E3 ligase cereblon (CRBN) modulator with potent anti-tumour activity mediated through the degradation of GSPT1. |
|
| DC12532 | CC-90003 | CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel. |
|
| DC12590 | CCB 02 Featured | CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin. |
|
| DC23540 | CCC07-01 | CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays. |
|
| DC7319 | CCDC(TGR5-Receptor-Agonist) Featured | CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8). |
|
| DC9757 | CCF642 Featured | CCF642 is a novel protein disulfide isomerases (PDI) inhibitor. |
|
| DC20867 | CCG 102487 | CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth. |
|
| DC20871 | CCG 2979 | CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor. |
|
| DC7979 | CCG1423 Featured | CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. |
|
| DC10535 | CCG-203971 Featured | CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. |
|
| DC11302 | CCG215022 Featured | CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively. |
|
| DC10977 | CCG-222740 | CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay. |
|
| DC20869 | CCG-232601 | CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF. |
|
| DC22819 | CCG-50014 Featured | CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. |
|
| DC9612 | CCG-63802 | CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. |
|
| DC9613 | CCG-63808 | CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. |
|
| DC22050 | CCI-006 | CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. |
|
| DC22049 | CCI-007 | CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485. |
|
| DC26030 | CCMI Featured | CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). |
|
| DC12639 | CCR1 inhibitor 19e | CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
|
| DC23528 | CCR10 antagonist 1 | CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM. |
|
| DC12177 | CCR2 antagonist 1 | CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
|
